Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Abx464
1. Abx-464
2. Abx464
3. Obefazimod
4. 1258453-75-6
5. Spl-464
6. Obefazimod [usan]
7. 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
8. 26ru378b9v
9. 2-quinolinamine, 8-chloro-n-(4-(trifluoromethoxy)phenyl)-
10. Obefazimod [inn]
11. Unii-26ru378b9v
12. Schembl1705888
13. Abx-464 [who-dd]
14. Chembl4297344
15. Gtpl11698
16. Ex-a3322
17. Who 12112
18. Db14828
19. Mmv1581032
20. Sb18690
21. Ac-35811
22. Bs-14770
23. Abx464(abx-464;abx 464)
24. Hy-100870
25. Cs-0020537
26. S0076
27. A16912
28. D84095
29. Q27896117
| Molecular Weight | 338.71 g/mol |
|---|---|
| Molecular Formula | C16H10ClF3N2O |
| XLogP3 | 5.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Exact Mass | 338.0433751 g/mol |
| Monoisotopic Mass | 338.0433751 g/mol |
| Topological Polar Surface Area | 34.2 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 388 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
ABX464 (obefazimod) is a novel, first-in-class, orally administered small molecule, which is being evaluated for treatment of moderately to severely active ulcerative colitis.
Lead Product(s): Obefazimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2025
Lead Product(s) : Obefazimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abivax Completes Enrollment in Phase 3 Trials for Ulcerative Colitis
Details : ABX464 (obefazimod) is a novel, first-in-class, orally administered small molecule, which is being evaluated for treatment of moderately to severely active ulcerative colitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2025
Details:
ABX464 (obefazimod) is an oral small molecule that was demonstrated to potentially enhance the expression of miR-124, being evaluated for moderate to severe ulcerative colitis.
Lead Product(s): Obefazimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 09, 2025
Lead Product(s) : Obefazimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
Details : ABX464 (obefazimod) is an oral small molecule that was demonstrated to potentially enhance the expression of miR-124, being evaluated for moderate to severe ulcerative colitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2025
Details:
Abivax is actively conducting preclinical studies ABX-464 (obefazimod) in combination with Etrasimod for treating Inflammatory Bowel Disease (IBD) in the Mouse Model.
Lead Product(s): Obefazimod,Etrasimod
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 25, 2024
Lead Product(s) : Obefazimod,Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abivax Presents Preclinical Data for UC Therapy with Obefazimod and Etrasimod
Details : Abivax is actively conducting preclinical studies ABX-464 (obefazimod) in combination with Etrasimod for treating Inflammatory Bowel Disease (IBD) in the Mouse Model.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2024
Details:
Undisclosed
Lead Product(s): Obefazimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 13, 2024
Lead Product(s) : Obefazimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 13, 2024
Details:
ABX464 (obefazimod) is an oral small molecule that was demonstrated to potentially enhance the expression of miR-124, being evaluated for moderate to severe ulcerative colitis.
Lead Product(s): Obefazimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2024
Lead Product(s) : Obefazimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abivax Reports Positive Interim Efficacy Analysis of Obefazimod in Ulcerative Colitis
Details : ABX464 (obefazimod) is an oral small molecule that was demonstrated to potentially enhance the expression of miR-124, being evaluated for moderate to severe ulcerative colitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2024
Details:
ABX464 (obefazimod) is an oral small molecule that was demonstrated to potentially enhance the expression of miR-124, being evaluated for moderate to severe crohn’s disease.
Lead Product(s): Obefazimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2024
Lead Product(s) : Obefazimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abivax Announces First Patient Enrolled in ENHANCE-CD Trial of Obefazimod in Crohn’s
Details : ABX464 (obefazimod) is an oral small molecule that was demonstrated to potentially enhance the expression of miR-124, being evaluated for moderate to severe crohn’s disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2024
Details:
The proceeds are expected to be allocated mainly to the development of ABX464 (obefazimod), an oral, first-in-class, small molecule, for the treatment of adults with moderately to severely active UC and other potential chronic inflammatory indications.
Lead Product(s): Obefazimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Kreos Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing August 21, 2023
Lead Product(s) : Obefazimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Kreos Capital
Deal Size : Undisclosed
Deal Type : Financing
Abivax Secures Up to EUR 150M from Two Structured Debt Financing Transactions
Details : The proceeds are expected to be allocated mainly to the development of ABX464 (obefazimod), an oral, first-in-class, small molecule, for the treatment of adults with moderately to severely active UC and other potential chronic inflammatory indications.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 21, 2023
Details:
ABX464 (Obefazimod), is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miR-124) with potent anti-inflammatory properties.
Lead Product(s): Obefazimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 01, 2023
Lead Product(s) : Obefazimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abivax Publishes Novel Data with Respect to Obefazimod’s Anti-Inflammatory Mechanism of Action
Details : ABX464 (Obefazimod), is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miR-124) with potent anti-inflammatory properties.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 01, 2023
Details:
ABX464 (Obefazimod), is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miR-124) with potent anti-inflammatory properties.
Lead Product(s): Obefazimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 17, 2023
Lead Product(s) : Obefazimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABX464 (Obefazimod), is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miR-124) with potent anti-inflammatory properties.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2023
Details:
The Company plans to use the net proceeds for the launch and continuation of the clinical programs of ABX464 (obefazimod), the Company's lead drug candidate in clinical development for ulcerative colitis.
Lead Product(s): Obefazimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: TCGX
Deal Size: $137.7 million Upfront Cash: Undisclosed
Deal Type: Financing February 22, 2023
Lead Product(s) : Obefazimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : TCGX
Deal Size : $137.7 million
Deal Type : Financing
Details : The Company plans to use the net proceeds for the launch and continuation of the clinical programs of ABX464 (obefazimod), the Company's lead drug candidate in clinical development for ulcerative colitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 22, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
43
PharmaCompass offers a list of Obefazimod API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Obefazimod manufacturer or Obefazimod supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Obefazimod manufacturer or Obefazimod supplier.
PharmaCompass also assists you with knowing the Obefazimod API Price utilized in the formulation of products. Obefazimod API Price is not always fixed or binding as the Obefazimod Price is obtained through a variety of data sources. The Obefazimod Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Obefazimod manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Obefazimod, including repackagers and relabelers. The FDA regulates Obefazimod manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Obefazimod API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Obefazimod supplier is an individual or a company that provides Obefazimod active pharmaceutical ingredient (API) or Obefazimod finished formulations upon request. The Obefazimod suppliers may include Obefazimod API manufacturers, exporters, distributors and traders.
Obefazimod Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Obefazimod GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Obefazimod GMP manufacturer or Obefazimod GMP API supplier for your needs.
A Obefazimod CoA (Certificate of Analysis) is a formal document that attests to Obefazimod's compliance with Obefazimod specifications and serves as a tool for batch-level quality control.
Obefazimod CoA mostly includes findings from lab analyses of a specific batch. For each Obefazimod CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Obefazimod may be tested according to a variety of international standards, such as European Pharmacopoeia (Obefazimod EP), Obefazimod JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Obefazimod USP).
